US FDA to hold public meeting on highly multiplexed microbiology diagnostics
This article was originally published in Clinica
Executive Summary
The US Food and Drug Administration is planning to hold a public meeting on 13 October to discuss performance evaluation of highly multiplexed microbiology/medical countermeasure (MCM) devices, their clinical application and public health needs, and quality criteria for establishing the accuracy of reference databases.